Table 1 Univariate survival analysis of relapse free and overall survival of 92 patients with primary breast cancer diagnosed and treated at the Medical University of Innsbruck, AT.

From: The BH3-only protein NOXA serves as an independent predictor of breast cancer patient survival and defines susceptibility to microtubule targeting agents

Variable

 

Relapse-free survival

Overall survival

  

Median, years (95% CI)

P-value (logrank-test)

Median, years (95% CI)

P-value (logrank-test)

Size

T1

n.r.

0.150

n.r.

0.093

 

T2/3/4

8.09 (0.00–19.35)

 

10.44 (4.62–16.25)

 

LN

Negative

n.r.

0.112

n.r.

0.007

 

Positive

n.r.

 

9.93 (6.35–13.50)

 

Tumour grade

I

n.r.

0.609

10.73 (8.69–12.78)

0.886

 

II

8.09 (n.r.)

 

14.64 (8.81–20.47)

 
 

III

n.r.

 

16.91 (8.76–20.06)

 

Histology

invasive lobular breast cancer

n.r.

0.187

18.69 (5.86–31.53)

0.905

 

invasive ductal breast cancer

8.09 (0.00–17.91)

 

12.15 (6.51–17.79)

 
 

medullary breast cancer

n.r.

 

16.91 (5.20–28.62)

 

MP

premenopausal

8.09 (0.00–19.69)

0.492

n.r

0.106

 

postmenopausal

n.r.

 

10.73 (5.33–16.14)

 

HER2

neg

n.r.

0.127

16.91 (12.90–20.92)

0.067

 

pos

5.23 (3.85–6.62)

 

7.25 (3.22–11.28)

 

ER

neg

n.r.

0.646

16.91 (5.01–28.81)

0.696

 

pos

19.23 (2.81–35.65)

 

14.64 (8.94–20.35)

 

PR

neg

n.r.

0.709

10.20 (0.00–22.45)

0.376

 

pos

19.23 (3.15–35.32)

 

14.64 (9.48–19.80)

 

MTA chemotherapy

no

5.95 (0.00–16.78)

0.057

8.76 (6.60–10.92)

0.001

 

yes

nr.

 

n.r.

 

Radiation therapy

no

n.r.

0.316

14.64 (9.68–19.61)

0.870

 

yes

6.77 (0.00–17.27)

 

17.78 (9.74–25.83)

 

Endocrine therapy

no

n.r.

0.658

14.64 (4.38–24.90)

0.601

 

yes

8.09 (0.00–18.43)

 

12.15 (6.23–18.07)

 

BCL2 mRNA expression

low (≤48th percentile)

4.72 (2.07–7.36)

0.003

8.59 (2.04–15.14)

0.117

 

high (>48th percentile)

n.r.

 

15.46 (7.41–23.52)

 

MCL1 mRNA expression

low (≤53rd percentile)

5.95 (n.r.)

0.128

9.35 (7.11–11.59)

0.014

 

high (>53rd percentile)

19.23 (n.r.)

 

17.95 (n.r.)

 

NOXA mRNA expression

low (≤12th percentile)

1.98 (1.44–2.52)

<0.001

3.28 (1.64–4.92)

<0.001

 

high (>12th percentile)

n.r.

 

16.91 (13.39–20.43)

 

BOK mRNA expression

low (≤34th percentile)

n.r.

0.008

n.r.

0.010

 

high (>34th percentile)

5.95 (2.70–9.20)

 

10.44 (6.92–13.96)

 
  1. Note: The significance level (P) was determined by log-rank test.
  2. LN lymph node status, MP menopausal status, HER2 human epidermal growth factor receptor 2 status, ER oestrogen receptor status, PR progesterone receptor status, HR hormone receptor status, n.r. not reached.
  3. p values that are statistically significant are shown in bold.
Back to article page